Terbinafine: Tolerability in general medical practice

British Journal of Dermatology, Supplement

Volumn 141, Issue 56, 1999, Pages 21-25

  O'Sullivan, D P ^a  

^a Novartis Pharmaceuticals Uk Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; TERBINAFINE;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAIL INFECTION; ONYCHOMYCOSIS; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 0032738528     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.00010.x     Document Type: Conference Paper

References (5)

1. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275-87.
2. O'Sullivan DP, Needham CA, Bangs A et al. Postmarketing surveillance of oral terbinafine in the UK. Br J Clin Pharmacol 1996; 42: 559-65.
3. Hall M, Monka C, Krupp P et al. Safety of oral terbinafine. Results of a postmarketing surveillance in 25,884 patients. Arch Dermatol 1997; 133: 1213-19.
4. Back DK, Stevenson P, Tija JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28: 166-70.
5. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 (Suppl. 39): 61-9.